06967nam 2202041z- 450 991040408700332120231214133603.03-03928-639-0(CKB)4100000011302268(oapen)https://directory.doabooks.org/handle/20.500.12854/58186(EXLCZ)99410000001130226820202102d2020 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierRenal Cell CarcinomaMDPI - Multidisciplinary Digital Publishing Institute20201 electronic resource (500 p.)9783039286386 Renal cancer is a health problem of major concern worldwide. Although tyrosine kinase inhibitors and immune check-point blockade treatments, alone or in combination, are giving promising results, failures are quite frequent due to intratumor heterogeneity and to the acquisition of drug resistance. The spectrum of renal cell carcinoma subtypes is wide. Up to 70–80% of renal tumors are clear cell renal cell carcinomas, a clinically aggressive tumor subtype linked to VHL gene inactivation. Next in frequency, the papillary renal cell carcinoma category encompasses an intricate puzzle of classic and newly described entities with poorly defined limits, some of them pending definite clarification. Likewise, the chromophobe–oncocytoma duality, the so-called hybrid tumors and oncocytic neoplasms, remain to be well profiled. Finally, a growing list of very uncommon renal tumors linked to specific molecular signatures fulfill the current portrait of renal cell neoplasia. This Special Issue of Cancers regards RCC from very different perspectives, from the intimate basic mechanisms governing this disease to the clinical practice principles of their diagnoses and treatments. The interested reader will have the opportunity to contact with some of the most recent findings and will be updated with excellent reviews.Renal cell carcinomaKidneysCancerN-glycomappingSMAD proteinspatient survivalpro-IL-1?survival predictioninflammation markerstumor migrationprognostic factorspractical approachcircular RNAs in a clinico-genomic predictive modelglycomarkersreviewnephrectomyuric acidVEGF inhibitorsmetabolic reprogrammingcollecting duct carcinomacurcuminmetabolome profilingidentification of circular RNAsIL-2experimental validation of circular RNARaf/MEK/ERKHOTPI3K/Akt/mTORpentose phosphate pathwaykidney cancerLOTmutationRCCpolybromo-1pale cellMMP-9gene expressionrecurrence free survivalchromosomal lossIL-1?chronic kidney diseaseglutathione transferase omega 2label-freeglutathione transferase omega 1emerging entitycopy number alterationFOXO3predictive roletumor slice culturetyrosine kinase inhibitorsPPPESCCDKN1A expressionmetastasisPD-L1diagnostic and prognostic markersEVI1copy number lossRNA sequencingNK cellsglutathione metabolismclear cell renal cell carcinomarenal cell cancerproliferationeosinophilic variantXp11 translocation renal cell carcinomaprognosisinvasionimmune infiltrationIL4R?FISH11) translocation renal cell carcinomatumor microenvironmentmetabolomehyperosmolalitytoxicityALKdrug sensitivityt(6copy number analysisurinegenetic associationpolymorphismsolute carrier proteinskidneymetastatic ccRCCmolecular genetic featuresrecurrence-free survivalchromophobe renal cell carcinomaunclassified renal tumoroverall survivalmTOR inhibitorsmTORJAK2von Hippel-LindaumiR-155-5pglycoproteomicsPBRM1miR-133bsurvivalTFE3TFEBoncocytic renal tumorimmune checkpoint inhibitorsbiomarkerMMP10TCGAghrelinEMT likecheckpoint inhibitorsMiT family translocation renal cell carcinomagene signaturesarcomatoidtransforming growth factor betaclear cell Renal Cell Carcinomatumor adhesionrenal cancerunclassified renal cell carcinomaPapillary renal cell carcinoma (pRCC)miR-146a-5prenal celleverolimusintegrinscytoreductive nephrectomyimmunotherapypredictive factorsimmunohistochemistryMTA2IL13R?1targeted therapyintratumour heterogeneityaurora ATCA cycleAMP-activated protein kinasescancer-specific survivalprogrammed death-ligand 1efficacyrenal cell carcinomaanaplastic lymphoma kinase rearrangementTFEB-amplified renal cell carcinomastatinscancer immunotherapymicroRNAnew entityproteome profilingRenal cell carcinoma.KidneysCancer.López José Iauth0BOOK9910404087003321Renal Cell Carcinoma2809988UNINA